Abstract
Background: Several promising biomarkers have been found for RCC, but none of them has been used in clinical practice for predicting tumour progression. The most widely used features for predicting tumour aggressiveness still remain the cancer stage, size and grade. Therefore, the aim of our study is to investigate the urinary peptidome to search and identify peptides whose concentrations in urine are linked to tumour growth measure and clinical data. Methods: A proteomic approach applied to ccRCC urinary peptidome (n = 117) based on prefractionation with activated magnetic beads followed by MALDI-TOF profiling was used. A systematic correlation study was performed on urinary peptide profiles obtained from MS analysis. Peptide identity was obtained by LC-ESI-MS/MS. Results: Fifteen, twenty-six and five peptides showed a statistically significant alteration of their urinary concentration according to tumour size, pT and grade, respectively. Furthermore, 15 and 9 signals were observed to have urinary levels statistically modified in patients at different pT or grade values, even at very early stages. Among them, C1RL, A1AGx, ZAG2G, PGBM, MMP23, GP162, ADA19, G3P, RSPH3, DREB, NOTC2 SAFB2 and CC168 were identified. Conclusions: We identified several peptides whose urinary abundance varied according to tumour size, stage and grade. Among them, several play a possible role in tumorigenesis, progression and aggressiveness. These results could be a useful starting point for future studies aimed at verifying their possible use in the managements of RCC patients.
| Original language | English |
|---|---|
| Article number | 332 |
| Journal | Journal of Translational Medicine |
| Volume | 13 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Oct 20 2015 |
Fingerprint
Keywords
- Cancer
- Grade
- Mass spectrometry
- Peptidomics
- Proteomics
- Renal cell carcinoma
- Stage
- Tumour progression
- Tumour size
- Urine
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Medicine(all)
Cite this
Tumor size, stage and grade alterations of urinary peptidome in RCC. / Chinello, Clizia; Cazzaniga, Marta; Sio, Gabriele; Smith, Andrew James; Grasso, Angelica; Rocco, Bernardo; Signorini, Stefano; Grasso, Marco; Bosari, Silvano; Zoppis, Italo; Mauri, Giancarlo; Magni, Fulvio.
In: Journal of Translational Medicine, Vol. 13, No. 1, 332, 20.10.2015.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tumor size, stage and grade alterations of urinary peptidome in RCC
AU - Chinello, Clizia
AU - Cazzaniga, Marta
AU - Sio, Gabriele
AU - Smith, Andrew James
AU - Grasso, Angelica
AU - Rocco, Bernardo
AU - Signorini, Stefano
AU - Grasso, Marco
AU - Bosari, Silvano
AU - Zoppis, Italo
AU - Mauri, Giancarlo
AU - Magni, Fulvio
PY - 2015/10/20
Y1 - 2015/10/20
N2 - Background: Several promising biomarkers have been found for RCC, but none of them has been used in clinical practice for predicting tumour progression. The most widely used features for predicting tumour aggressiveness still remain the cancer stage, size and grade. Therefore, the aim of our study is to investigate the urinary peptidome to search and identify peptides whose concentrations in urine are linked to tumour growth measure and clinical data. Methods: A proteomic approach applied to ccRCC urinary peptidome (n = 117) based on prefractionation with activated magnetic beads followed by MALDI-TOF profiling was used. A systematic correlation study was performed on urinary peptide profiles obtained from MS analysis. Peptide identity was obtained by LC-ESI-MS/MS. Results: Fifteen, twenty-six and five peptides showed a statistically significant alteration of their urinary concentration according to tumour size, pT and grade, respectively. Furthermore, 15 and 9 signals were observed to have urinary levels statistically modified in patients at different pT or grade values, even at very early stages. Among them, C1RL, A1AGx, ZAG2G, PGBM, MMP23, GP162, ADA19, G3P, RSPH3, DREB, NOTC2 SAFB2 and CC168 were identified. Conclusions: We identified several peptides whose urinary abundance varied according to tumour size, stage and grade. Among them, several play a possible role in tumorigenesis, progression and aggressiveness. These results could be a useful starting point for future studies aimed at verifying their possible use in the managements of RCC patients.
AB - Background: Several promising biomarkers have been found for RCC, but none of them has been used in clinical practice for predicting tumour progression. The most widely used features for predicting tumour aggressiveness still remain the cancer stage, size and grade. Therefore, the aim of our study is to investigate the urinary peptidome to search and identify peptides whose concentrations in urine are linked to tumour growth measure and clinical data. Methods: A proteomic approach applied to ccRCC urinary peptidome (n = 117) based on prefractionation with activated magnetic beads followed by MALDI-TOF profiling was used. A systematic correlation study was performed on urinary peptide profiles obtained from MS analysis. Peptide identity was obtained by LC-ESI-MS/MS. Results: Fifteen, twenty-six and five peptides showed a statistically significant alteration of their urinary concentration according to tumour size, pT and grade, respectively. Furthermore, 15 and 9 signals were observed to have urinary levels statistically modified in patients at different pT or grade values, even at very early stages. Among them, C1RL, A1AGx, ZAG2G, PGBM, MMP23, GP162, ADA19, G3P, RSPH3, DREB, NOTC2 SAFB2 and CC168 were identified. Conclusions: We identified several peptides whose urinary abundance varied according to tumour size, stage and grade. Among them, several play a possible role in tumorigenesis, progression and aggressiveness. These results could be a useful starting point for future studies aimed at verifying their possible use in the managements of RCC patients.
KW - Cancer
KW - Grade
KW - Mass spectrometry
KW - Peptidomics
KW - Proteomics
KW - Renal cell carcinoma
KW - Stage
KW - Tumour progression
KW - Tumour size
KW - Urine
UR - http://www.scopus.com/inward/record.url?scp=84945182108&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945182108&partnerID=8YFLogxK
U2 - 10.1186/s12967-015-0693-8
DO - 10.1186/s12967-015-0693-8
M3 - Article
AN - SCOPUS:84945182108
VL - 13
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
SN - 1479-5876
IS - 1
M1 - 332
ER -